Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension

Oral treprostinil (TRE) is a prostacylin that is approved for the treatment of patients with pulmonary arterial hypertension (PAH). Dosing is approved for two or three times daily (t.i.d.); however, adverse effects, including gastrointestinal-related symptoms, may limit the ability to reach optimal...

Descripción completa

Detalles Bibliográficos
Autores principales: Coons, James C., Bunner, Cheryl, Ishizawar, David C., Risbano, Michael G., Rivera-Lebron, Belinda, Mathier, Michael A., Chan, Stephen Y., Simon, Marc A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731722/
https://www.ncbi.nlm.nih.gov/pubmed/29199910
http://dx.doi.org/10.1177/2045893217744512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731722/
https://www.ncbi.nlm.nih.gov/pubmed/29199910
http://dx.doi.org/10.1177/2045893217744512

Ejemplares similares